News Article | May 1, 2017
ROSEMONT, Ill. (May 1, 2017)--Nearly one in 1,000 pregnant women in the United States suffer bone and joint injuries due to car crashes, domestic violence, drug or alcohol use, or osteoporosis. According to a literature review in the May 2017 issue of the Journal of the American Academy of Orthopaedic Surgeons, the stage of a woman's pregnancy--how her body may have changed during the course of the pregnancy--needs to be factored into the mother and fetus' orthopaedic trauma care. Bodily changes during pregnancy affect every step of the orthopaedic trauma treatment process, including prescription of medications and surgical management. Treatment of pregnant patients with bone and joint injuries can be complicated and requires a team of specialists from multiple disciplines. "Awareness and knowledge of maternal physiology and anatomy, radiation procedures and risks, teratogenic agents [i.e., infections, chemicals and drugs] and proper surgical techniques can significantly improve maternal outcomes without jeopardizing fetal health," says lead author Nirmal Tejwani, MD, an orthopaedic trauma surgeon with NYU Langone Orthopedics. "When pregnant women sustain fractures, two lives must be simultaneously treated throughout the entire process," says Dr. Tejwani. Fetal monitoring before and during any surgical procedure, and a collaborative team of well-trained specialists are essential for optimal patient outcomes. "Under fetal monitoring before and during surgery, a 22-year-old woman--who fractured her right shin bone while six weeks pregnant--underwent anesthesia and a successful fracture repair. Her fracture healed satisfactorily in three months, and she was able to later deliver a healthy baby at term." Although the cause of orthopaedic traumas vary, pregnant women and their unborn babies are most vulnerable to injuries in motor vehicle crashes. Among those injured as drivers or passengers, up to 64 percent were not wearing seat belts at the time of the collision, which can cause harm to the mother and fetus. "The most preventable factor is wearing a seat belt. Pregnant women typically don't wear seat belts because they feel this harms the fetus; however, they should be counseled on the importance of seat belt use in preventing maternal and fetal harm," says Dr. Tejwani. In orthopaedic trauma care, "the health of the mother is always prioritized over the fetus," says Dr. Tejwani. "Surgery should be delayed, if possible, until after delivery of the newborn to minimize any risk of harm. Sometimes, the fetus may be delivered before fracture fixation if near term." In one case, Dr. Tejwani and a team of physicians deemed it safer to induce delivery for a 39-year-old woman injured in a car crash as a pedestrian. She suffered a fracture-dislocation of her ankle--an unstable injury involving bone and soft tissue--and was 37 weeks pregnant. After delivery, the patient was given an epidural, and her ankle fracture was reduced and splinted. A few days later, she underwent surgery with anesthesia, was counselled about swelling in her lower body--which is usually greater among pregnant patients with ankle fractures--prescribed pain medication to be used sparingly, and was advised to not breastfeed until after the medications were stopped. By the numbers, pregnant patients with orthopaedic trauma when compared with non-trauma patients: More information about the AAOS Follow the AAOS on Facebook and Twitter Follow the conversation about JAAOS on Twitter From the NYU Langone Orthopedics, New York, N.Y. (Dr. Nirmal Tejwani, Dr. Christopher Looze, and Dr. Christopher Klifto), and the Philadelphia College of Osteopathic Medicine, Philadelphia, Pa. (Dr. Kevin Klifto). Dr. Tejwani or an immediate family member is a member of a speakers' bureau or has made paid presentations on behalf of and serves as a paid consultant to Stryker and Zimmer Biomet and serves as a board member, owner, officer, or committee member of the American Academy of Orthopaedic Surgeons, the Foundation for Orthopaedic Trauma, and the Orthopaedic Trauma Association. Dr. Looze or an immediate family member is an employee of Amgen. Dr. C. Klifto or an immediate family member has stock or stock options held in GE Healthcare, Johnson & Johnson, Merck, and Pfizer. Neither Dr. K. Klifto nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article.
News Article | April 26, 2017
— Global Lower Extremities Market 2017-2021 is growing popularity of MI procedures. Traditional open surgeries can cause post-operation complications such as pain, partially collapsed lungs, blood clots, fatigue, muscle atrophy, and infections. The anesthesia administered before surgeries can cause nausea, sore throat, confusion, and sleepiness. To reduce such complications, medical facilities have started implementing MI techniques in their surgical procedures. Complete report on lower extremities market spread across 70 pages, analyzing 3 major companies and provides 58 data exhibits is now available at http://www.reportsnreports.com/reports/966148-global-lower-extremities-market-2017-2021.html . The report, Global Lower Extremities Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. According to the lower extremities market report, one driver in market is hip replacement procedures in UK. The joint replacement surgeries such as hip and knee replacement and revision procedures are increasing the need for lower extremity products in the market. For the replacement procedure, artificial implants are used, which replaces the joints in hip and knees. In 2002, the National Joint Registry was set up by the Department of Health and Welsh Government, UK. The registry collects the orthopedic reconstruction data from the NHS and procedures performed in the NHS hospitals. According to the National Joint Registry, the number of revision hip replacement procedures performed in 2014 and 2015 were 8,176 and 7,214, respectively. For hip replacement revision cases, a dip in the number of cases was observed in 2015 owing to the increased use of advanced lower extremity products. The analysts forecast global lower extremities market to grow at a CAGR of 7.66% during the period 2017-2021. Key players in the global lower extremities market: DePuy Synthes, Stryker, and Zimmer Biomet. Other Prominent Vendors in the market are: Active Implants, Acumed, Arthrex, Avitus Orthopaedics, Biotech Limb and Brace, Bioventus, Bone Therapeutics, Bone Biologics, Ceramisys, ConforMIS, CONMED, CollPlant, DJO Global, Evolutis, Exactech, FH Orthopedics, Graftys, ICONACY Orthopedic Implants, Integra LifeSciences, implantcast, Isto Biologics , Lima Corporate, Medtronic, Merete Group, Össur, OsteoMed, Orthofix, Orthogem, Promedics Orthopaedic, Regenexx,, RTI Surgical, Sigma Graft, Silver Bullet Therapeutics, Skye Biologics, Smith & Nephew, Stanmore Implants Worldwide, Surgical Appliance Industries, Wright Medical Group, and Xtant Medical. Further, the report states that one challenges in market is high procedure cost. Hospitals and surgical centers are under constant pressure to deliver quality care at low cost. However, this has become difficult due to the implementation of advanced procedures that involve the use of sophisticated devices. Hospitals and ASCs need to consider various procurement processes and budget allocation considerations before purchasing such devices. To increase their budget, hospitals sometimes implement the procedure cost, which can be high for the individuals. It increases cost burden on them, which hinders the market adoption. High procedure cost can impact the market growth negatively. About Us: ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/966148-global-lower-extremities-market-2017-2021.html
News Article | April 26, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Tourniquets Device Market 2017-2021" report to their offering. The global tourniquets device market to grow at a CAGR of 8.95% during the period 2017-2021. The report, Global Tourniquets Device Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. According to the report, one driver in market is technological advances. The growing focus toward the incorporation of technological advances by vendors to develop advanced tourniquets is expected to fuel the market growth. The market has witnessed a shift from manual tourniquets to technologically advanced tourniquets. For instance, Stryker is offering Color Cuff sterile disposable tourniquets, which is available in single or dual port configurations to reduce cross contamination issues. Also, Zimmer Biomet is offering the A.T.S 4000 tourniquet system, which includes personalized pressure technology, dual port, and dual cuff assisted gas monitors. Also, companies such as ulrich medical and Delfi Medical are offering inflatable abdominal tourniquets, which help reduce heavy bleeding with an incredibly simple and mechanical design. This device can be buckled around an individual's abdomen, over the belly button, and then tightened. A hand pump is used to inflate a wedge-shaped bladder, which displaces the bowel and compresses the individual's aorta against the spine, stopping all blood flow to the lower body. For more information about this report visit http://www.researchandmarkets.com/research/49jmf5/global
News Article | April 21, 2017
LONDON, UK / ACCESSWIRE / April 21, 2017 / Active Wall St. announces its post-earnings coverage on Intuitive Surgical, Inc. (NASDAQ: ISRG). The Company posted its first quarter fiscal 2017 results on April 18, 2017. The robotic surgery system Company surpassed top- and bottom-line expectations. Register with us now for your free membership at: http://www.activewallst.com/register/. One of Intuitive Surgical's competitors within the Medical Appliances & Equipment space, Zimmer Biomet Holdings, Inc. (NYSE: ZBH), is estimated to report earnings on April 27, 2017. AWS will be initiating a research report on Zimmer Biomet following the release of its next earnings results. Today, AWS is promoting its earnings coverage on ISRG; touching on ZBH. Get our free coverage by signing up to: http://www.activewallst.com/register/. For the three months ended March 31, 2017, Intuitive Surgical's revenue was $674 million, up approximately 13% compared with $595 million in Q1 FY16. The increase in revenue was driven by growth in recurring instrument, accessory, and service revenue, and higher systems revenue. The Company's revenue numbers surpassed analysts' consensus of $660.6 million. For Q1 FY17, Intuitive Surgical's instrument and accessory revenue had increased by approximately 18% to $381 million compared with $322 million for Q1 FY16, primarily driven by nearly 18% growth in da Vinci procedure volume. The Company's service revenue had increased by approximately 13% to $140 million in the reported quarter compared with $125 million in the year earlier same quarter. For Q1 FY17, Intuitive Surgical's systems revenue increased by approximately 4% to $153 million compared with $148 million for Q1 FY16. Intuitive Surgical shipped 133 da Vinci Surgical Systems in the reported quarter compared with 110 in the year earlier comparable quarter. Intuitive Surgical's Q1 FY17 income from operations increased to $192 million compared with $179 million in Q1 FY16. The Company's reported quarter non-GAAP income from operations increased to $264 million compared with $229 million in the year earlier corresponding quarter. Intuitive Surgical's Q1 FY17 GAAP net income was $180 million, or $4.67 per diluted share, compared with $136 million, or $3.54 per diluted share, for Q1 FY16. The Company's reported quarter GAAP net income benefited from the adoption of a new accounting standard which required that $33 million, or $0.85 per share, of excess tax benefits related to employee share-based compensation awards be recorded as a component of income tax expense. For Q1 FY17 results also included pre-tax litigation charges of approximately $21 million, or $0.39 per share net of income tax. The Company's non-GAAP net income was $196 million, or $5.09 per diluted share, for the reported quarter compared with $170 million, or $4.42 per diluted share, for the prior year quarter. The results topped Wall Street's estimates of $4.90 per share. For Q1 FY17, Intuitive Surgical's worldwide da Vinci procedures grew nearly 18% on a y-o-y basis, driven primarily by growth in US general surgery procedures and worldwide urologic procedures. The Company shipped 133 da Vinci Surgical Systems in the reported quarter compared with 110 in the year earlier same quarter. Intuitive Surgical ended Q1 FY17 with $3.1 billion in cash, cash equivalents, and investments, a decrease of $1.7 billion during the reported quarter, primarily driven by the $2 billion used for accelerated share repurchases, yet partially offset by proceeds from cash generated from operations and employee stock option exercises. At the close of trading session on Thursday, April 20, 2017, Intuitive Surgical's share price finished yesterday's trading session at $814.45, rising slightly by 0.84%. A total volume of 394.36 thousand shares exchanged hands, which was higher than the 3 months average volume of 356.40 thousand shares. The stock has surged 23.77% and 26.36% in the last three months and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have surged 28.43%. The stock is trading at a PE ratio of 43.52 and currently has a market cap of $29.91 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
News Article | April 18, 2017
Tissue Engineering is a process involving in-vitro development of tissues or organs. It is done to replace or support the function of defective or injured body part. Tissue engineering involves the application of biology and engineering for innovation of tissue substitutes that can maintain, restore and improve the function of ruptured human tissue. Products developed by this procedure are efficient and durable. Tissue engineering is gaining its popularity in various areas such as burn treatment or wound care, neurology products, orthopedics, urological products and others. On the basis of type of material used, tissue engineering and regeneration market can be segmented into synthetic, genetically modified and biological materials. For more information or any query mail at email@example.com This report focuses on the Tissue Engineering in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers Allergan Integra Lifesciences C. R. Bard Zimmer Biomet Organogenesis Osiris Therapeutics Cryolife ACell Biocomposites DSM Episkin J-TEC Athersys Biotime B. Braun International Stem Cell Bio Tissue Technologies Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Columbia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Applications, can be divided into Orthopedics, Musculoskeletal & Spine Neurology Cardiology & Vascular Skin & Integumentary Others There are 15 Chapters to deeply display the global Tissue Engineering market. Chapter 2, to analyze the top manufacturers of Tissue Engineering, with sales, revenue, and price of Tissue Engineering, in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; 2 Manufacturers Profiles 2.1 Allergan 2.1.1 Business Overview 2.1.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.1.3 Allergan Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.2 Integra Lifesciences 2.2.1 Business Overview 2.2.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.2.3 Integra Lifesciences Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.3 C. R. Bard 2.3.1 Business Overview 2.3.2 Tissue Engineering Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.3.3 C. R. Bard Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.4 Zimmer Biomet 2.4.1 Business Overview 2.4.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.4.3 Zimmer Biomet Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.5 Organogenesis 2.5.1 Business Overview 2.5.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.5.3 Organogenesis Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.6 Osiris Therapeutics 2.6.1 Business Overview 2.6.2 Tissue Engineering Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.6.3 Osiris Therapeutics Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.7 Cryolife 2.7.1 Business Overview 2.7.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.7.3 Cryolife Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.8 ACell 2.8.1 Business Overview 2.8.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.8.3 ACell Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.9 Biocomposites 2.9.1 Business Overview 2.9.2 Tissue Engineering Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.9.3 Biocomposites Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.10 DSM 2.10.1 Business Overview 2.10.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.10.3 DSM Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.11 Episkin 2.11.1 Business Overview 2.11.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.11.3 Episkin Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.12 J-TEC 2.12.1 Business Overview 2.12.2 Tissue Engineering Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.12.3 J-TEC Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.13 Athersys 2.13.1 Business Overview 2.13.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.13.3 Athersys Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.14 Biotime 2.14.1 Business Overview 2.14.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.14.3 Biotime Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.15 B. Braun 2.15.1 Business Overview 2.15.2 Tissue Engineering Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.15.3 B. Braun Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.16 International Stem Cell 2.16.1 Business Overview 2.16.2 Tissue Engineering Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.16.3 International Stem Cell Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.17 Bio Tissue Technologies 2.17.1 Business Overview 2.17.2 Tissue Engineering Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.17.3 Bio Tissue Technologies Tissue Engineering Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 3 Global Tissue Engineering Market Competition, by Manufacturer 3.1 Global Tissue Engineering Sales and Market Share by Manufacturer 3.2 Global Tissue Engineering Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Tissue Engineering Manufacturer Market Share 3.3.2 Top 6 Tissue Engineering Manufacturer Market Share 3.4 Market Competition Trend For more information or any query mail at firstname.lastname@example.org ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com
News Article | April 26, 2017
— Global Spine Biologics Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are Medtronic, Depuy Synthes, Stryker Corporation, Nuvasive, Zimmer Biomet, Orthofix International, Globus Medical, Alphatec Spine, K2m, Exactech, Wright Medical Technology, X-Spine, Nutech, Arthrex in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • Bone Graft • Bone Graft Substitute • Platelet Rich Plasma (PRP) • BMAC (Bone Marrow Aspirate Concentrate) Split by applications, this report focuses on sales, market share and growth rate of Spine Biologics in each application, can be divided into • Anterior Cervical Discectomy and Fusion • Posterior Lumbar Interbody Fusion • Other Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/424280 Table of Content: 1 Spine Biologics Market Overview 2 Global Spine Biologics Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Spine Biologics Manufacturers Profiles/Analysis 5 North America Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Spine Biologics Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Spine Biologics Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Spine Biologics Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/424280 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-spine-biologics-market-report
News Article | April 25, 2017
Dental Laboratories -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021Pune , India - April 25, 2017 /MarketersMedia/ — Dental Laboratories Industry Description Wiseguyreports.Com Adds “Dental Laboratories -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database The Global Dental Laboratories Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratories industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Dental Laboratories market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/423910-global-dental-laboratories-industry-2016-market-research-two Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions (United States, EU, China and Japan), and other regions can be added. Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What’s more, the Dental Laboratories industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Leave a Query @ https://www.wiseguyreports.com/enquiry/423910-global-dental-laboratories-industry-2016-market-research-two Table of Contents 1 Industry Overview of Dental Laboratories 1.1 Definition and Specifications of Dental Laboratories 1.1.1 Definition of Dental Laboratories 1.1.2 Specifications of Dental Laboratories 1.2 Classification of Dental Laboratories 1.3 Applications of Dental Laboratories 1.4 Industry Chain Structure of Dental Laboratories 1.5 Industry Overview and Major Regions Status of Dental Laboratories 1.5.1 Industry Overview of Dental Laboratories 1.5.2 Global Major Regions Status of Dental Laboratories 1.6 Industry Policy Analysis of Dental Laboratories 1.7 Industry News Analysis of Dental Laboratories 2 Manufacturing Cost Structure Analysis of Dental Laboratories 2.1 Raw Material Suppliers and Price Analysis of Dental Laboratories 2.2 Equipment Suppliers and Price Analysis of Dental Laboratories 2.3 Labor Cost Analysis of Dental Laboratories 2.4 Other Costs Analysis of Dental Laboratories 2.5 Manufacturing Cost Structure Analysis of Dental Laboratories 2.6 Manufacturing Process Analysis of Dental Laboratories .... 8 Major Manufacturers Analysis of Dental Laboratories 8.1 3M ESPE (US) 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.3 Capacity, Production, Price, Cost, Gross and Revenue 8.1.4 Contact Information 8.2 A Plus Dental Laboratory (UK) 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.3 Capacity, Production, Price, Cost, Gross and Revenue 8.2.4 Contact Information 8.3 ADL Dental Laboratories (Canada) 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.3 Capacity, Production, Price, Cost, Gross and Revenue 8.3.4 Contact Information 8.4 Asteto Dent Labs (US) 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.3 Capacity, Production, Price, Cost, Gross and Revenue 8.4.4 Contact Information 8.5 Champlain Dental Laboratory Inc. (US) 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.3 Capacity, Production, Price, Cost, Gross and Revenue 8.5.4 Contact Information 8.6 Dental Services Group (US) 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.3 Capacity, Production, Price, Cost, Gross and Revenue 8.6.4 Contact Information 8.7 DENTSPLY International, Inc. (US) 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.3 Capacity, Production, Price, Cost, Gross and Revenue 8.7.4 Contact Information 8.8 Elysee Dental Solutions BV (Netherlands) 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.3 Capacity, Production, Price, Cost, Gross and Revenue 8.8.4 Contact Information 8.9 Flemming Dental Service GmbH (Germany) 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.3 Capacity, Production, Price, Cost, Gross and Revenue 8.9.4 Contact Information 8.10 Glidewell Laboratories (US) 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.3 Capacity, Production, Price, Cost, Gross and Revenue 8.10.4 Contact Information 8.11 Institut Straumann AG (Switzerland) 8.11.1 Company Profile 8.11.2 Product Picture and Specifications 8.11.3 Capacity, Production, Price, Cost, Gross and Revenue 8.11.4 Contact Information 8.12 Iverson Dental Laboratories (US) 8.12.1 Company Profile 8.12.2 Product Picture and Specifications 8.12.3 Capacity, Production, Price, Cost, Gross and Revenue 8.12.4 Contact Information 8.13 Knight Dental Design (UK) 8.13.1 Company Profile 8.13.2 Product Picture and Specifications 8.13.3 Capacity, Production, Price, Cost, Gross and Revenue 8.13.4 Contact Information 8.14 Lord's Dental Studio, Inc. (US) 8.14.1 Company Profile 8.14.2 Product Picture and Specifications 8.14.3 Capacity, Production, Price, Cost, Gross and Revenue 8.14.4 Contact Information 8.15 MicroDental Laboratories Inc. (US) 8.15.1 Company Profile 8.15.2 Product Picture and Specifications 8.15.3 Capacity, Production, Price, Cost, Gross and Revenue 8.15.4 Contact Information 8.16 Modern Dental Laboratory USA (US) 8.16.1 Company Profile 8.16.2 Product Picture and Specifications 8.16.3 Capacity, Production, Price, Cost, Gross and Revenue 8.16.4 Contact Information 8.17 National Dentex Corp. (US) 8.17.1 Company Profile 8.17.2 Product Picture and Specifications 8.17.3 Capacity, Production, Price, Cost, Gross and Revenue 8.17.4 Contact Information 8.18 Nobel Biocare Holding AG (Switzerland) 8.18.1 Company Profile 8.18.2 Product Picture and Specifications 8.18.3 Capacity, Production, Price, Cost, Gross and Revenue 8.18.4 Contact Information 8.19 Patriot Dental Laboratory (US) 8.19.1 Company Profile 8.19.2 Product Picture and Specifications 8.19.3 Capacity, Production, Price, Cost, Gross and Revenue 8.19.4 Contact Information 8.20 Shofu, Inc. (Japan) 8.20.1 Company Profile 8.20.2 Product Picture and Specifications 8.20.3 Capacity, Production, Price, Cost, Gross and Revenue 8.20.4 Contact Information 8.21 Southern Craft Dental Laboratory, Inc. (US) 8.21.1 Company Profile 8.21.2 Product Picture and Specifications 8.21.3 Capacity, Production, Price, Cost, Gross and Revenue 8.21.4 Contact Information 8.22 Swift Dental Laboratory Ltd. (UK) 8.22.1 Company Profile 8.22.2 Product Picture and Specifications 8.22.3 Capacity, Production, Price, Cost, Gross and Revenue 8.22.4 Contact Information 8.23 Utah Valley Dental Lab (US) 8.23.1 Company Profile 8.23.2 Product Picture and Specifications 8.23.3 Capacity, Production, Price, Cost, Gross and Revenue 8.23.4 Contact Information 8.24 Zimmer Biomet Holdings, Inc. (US) 8.24.1 Company Profile 8.24.2 Product Picture and Specifications 8.24.3 Capacity, Production, Price, Cost, Gross and Revenue 8.24.4 Contact Information Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=423910 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) Contact Info:Name: NORAH TRENTEmail: email@example.comOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028Phone: +91 841 198 5042Source URL: http://marketersmedia.com/dental-laboratories-market-2017-global-analysis-opportunities-and-forecast-to-2022/189995For more information, please visit https://www.wiseguyreports.com/enquiry/423910-global-dental-laboratories-industry-2016-market-research-twoSource: MarketersMediaRelease ID: 189995